Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15354487 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL7127556 | 0.92 | ALDH1A1 (0.51) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL18545126 | 0.92 | ALDH1A1 (0.43) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL29300492 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL13474979 | 0.88 | ALDH1A1 (0.50) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL29300493 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL24709151 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL19090093 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL22854887 | 0.87 | ALDH1A1 (0.66) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 | |
| SCHEMBL31646761 | 0.87 | ALDH1A1 (0.47) | ALDH1A1TDP1KDM4ESMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2022-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220211883-A1 | FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO | FAP, FIBP, FGFR1 | ALDH1A1 789/4885TDP1 283/4885KDM4E 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.